New cancer drug FID-022 enters first human trial

NCT ID NCT06694480

Recruiting now Disease control Sponsor: Fulgent Pharma LLC. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is already used in some cancer treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FID-022 (a drug containing two active components, one of which is irinotecan)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have few other choices.
What could go wrong: This is a very early, small phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or not work against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

USC/Norris Comprehensive Cancer Center and Hospital
RECRUITING

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.